



22 April 2022  
EMA/CHMP/219292/2022  
Committee for Medicinal Products for Human Use (CHMP)

## Summary of opinion<sup>1</sup> (post authorisation)

---

### Retsevmo selpercatinib

On 22 April 2022, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Retsevmo. The marketing authorisation holder for this medicinal product is Eli Lilly Nederland B.V.

The CHMP adopted an extension to an existing indication as follows:<sup>2</sup>

Retsevmo as monotherapy is indicated for the treatment of adults with advanced *RET* fusion positive non-small cell lung cancer (NSCLC) **not previously treated with a *RET* inhibitor** ~~who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.~~

For information, the full indication for Retsevmo will therefore be as follows:

Retsevmo as monotherapy is indicated for the treatment of adults with:

- advanced *RET* fusion-positive non-small cell lung cancer (NSCLC) not previously treated with a *RET* inhibitor
- advanced *RET* fusion-positive thyroid cancer who require systemic therapy following prior treatment with sorafenib and/or lenvatinib

Retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced *RET*-mutant medullary thyroid cancer (MTC) who require systemic therapy following prior treatment with cabozantinib and/or vandetanib.

Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), and will be available in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.

---

<sup>1</sup> Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion

<sup>2</sup> New text in bold, removed text as strikethrough

